Other Events. As previously announced, on August 13, 2026, CapsoVision, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 (the “Shares”) throu…

Results of Operations and Financial Condition. On August 13, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release, dated August 13, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor sha…

Entry into a Material Definitive Agreement. On August 13, 2026, CapsoVision, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 (the…

Director — Dr. David S. Shields: Appointment of Dr. David S. Shields as a Director to fill the vacancy upon the resignation of Dr. Imperial.

Results of Operations and Financial Condition. On May 14, 2026, the Company issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of the press release, dated May 14, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it…

Results of Operations and Financial Condition. On March 26, 2026, the Company issued a press release announcing its financial results for the fiscal year ended December 31, 2025. A copy of the press release, dated March 26, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shal…

Other Events. Update on CapsoCam Colon The Company is a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. Currently, the Company’s GI-tract capsule endoscopy solution comprises the single-use CapsoCam capsule and the associated software, CapsoCloud and CapsoView. In addition, the Company is developing its next pipeline capsule endoscope, CapsoCam Colon. The CapsoCam Colon capsule (i) leverages Ca…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On March 16, 2026, CapsoVision, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (the “Investors”), for the purposes of raising approximately $14 million in aggregate gross proceeds for the Company (the “Private Placement”). Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the Investors in the Private Placement…

Entry into a Material Definitive Agreement. As previously reported on Form 8-K filed by CapsoVision, Inc. (the “Company”) on July 15, 2026 (the “July 15th 2025 8-K”), the Company entered into a development agreement (the “Agreement”) with Canon Inc., a Japanese corporation (“Canon”), for the development of complementary metal-oxide-semiconductor (“CMOS”) image sensor samples to allow the Company to evaluate functionality and performance, conduct clinical evaluation of capsule endoscopies that…

Results of Operations and Financial Condition. On November 13, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release, dated November 13, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…

principal financial officer and principal accounting officer — David Garcia: David Garcia was promoted to serve as the Company’s principal financial officer and principal accounting officer.

Senior Director of Clinical Affairs — Rebecca Petersen: Ms. Rebecca Petersen is retiring and will be succeeded by Ms. Keri Jorgenson.

Chief Financial Officer — Kevin Lundquist: Kevin Lundquist has stepped down as Chief Financial Officer with no immediate successor.

Results of Operations and Financial Condition. On August 14, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release, dated August 14, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor sha…

Entry into a Material Definitive Agreement. On July 15, 2025, CapsoVision, Inc. (the “ Company ”) entered into a development agreement (the “ Agreement ”) with Canon Inc., a Japanese corporation (“ Canon ”), for the development of complementary metal-oxide-semiconductor (“ CMOS ”) image sensor samples to allow the Company to evaluate functionality and performance, conduct clinical evaluation of capsule endoscopies that incorporate Canon image sensors and obtain FDA 510(k) clearance thereof. T…

Entry into a Material Definitive Agreement. On July 1, 2025, CapsoVision, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with The Benchmark Company, LLC (“ Benchmark ”) and Roth Capital Partners, LLC (“ Roth ”), as representatives of the underwriters named therein (the “ Representatives ”), pursuant to which the Company issued and sold, in its initial public offering (the “ Public Offering ”), 5,500,000 shares of its common stock, $0.001 par val…